Yakult Honsha : China and Guangzhou to Start Selling 50 Billion Light
February 21, 2023 at 11:20 am IST
Share
Yakult China and Guangzhou Yakult to Start Selling
Yakult 50 Billion Light
Yakult Honsha Co., Ltd. (President: Hiroshi Narita) today announced that its overseas subsidiaries Yakult (China) Corporation and Guangzhou Yakult Co., Ltd. would start sales of Yakult 50 Billion Light, a high bacteria count, high value-added fermented milk drink from February 1, 2023.
There has been growing interest in health among consumers in China in recent years and demand for products with high bacteria counts has been growing in the fermented milk drink market. Against this backdrop, the Yakult Group aims to expand sales by introducing Yakult 50 Billion Light, which contains 50 billion of Yakult's proprietary Lactobacillus casei strain Shirota in addition to dietary fiber and nutrients such as vitamin D and E, and calcium.
The sales plan for Yakult 50 Billion Light by Yakult China and Guangzhou Yakult is as follows:
1.
Product name:
Yakult 50 Billion Light
2.
Size and package:
Packages of five 100 ml bottles
3.
Suggested retail price: 16.8 yuan (approx. 342 yen) per package
4.
Start of sales:
February 1, 2023, for the area covered by Guangzhou Yakult
February 6, 2023, for the area covered by Yakult China
5.
Sales channels:
Home delivery by Yakult Ladies
Hypermarkets, supermarkets, convenience stores, and other
retail channels
6.
Sales target:
408,000 bottles per day
(daily average sales from January through December 2023)
[Breakdown]
Yakult China:
295,000 bottles per day
Guangzhou Yakult:
114,000 bottles per day
Yakult 50 Billion Light sold by Yakult China
Yakult 50 Billion Light sold by Guangzhou Yakult
[Reference]
1. Profile of Yakult (China)
(1) Name:
Yakult (China) Corporation
(2) Capitalization:
1,491.52 million yuan (as of the end of June 2022)
(wholly owned by Yakult Honsha Co., Ltd.)
(3) Location:
Shanghai, People's Republic of China
(4) Representative:
Noriyuki Umehara
(5) Established:
April 2005
(6) Start of operations
April 2007
(7) Employees:
3,001 (as of the end of October 2022)
(8) Sales performance:
4,164,000 bottles per day (including sales by Yakult
Shanghai and Yakult Beijing)
(average for the January-December 2021 period)
(9) Sales area:
Mainland China other than Guangdong and Hainan
Provinces
2. Profile of Guangzhou Yakult Co., Ltd.
(1)
Name:
Guangzhou Yakult Co., Ltd.
(2)
Capitalization:
395.6 million yuan (as of the end of June 2022)
(50% held by Yakult Honsha Co., Ltd., 35% by
Hong Kong Yakult Co., Ltd., 10% by Yakult
(China) Corporation, and 5% by Guangzhou Sui
Zhi Investment Co., Ltd.)
(3) Location:
Tianhe District, Guangzhou, Guangdong
Province, People's Republic of China
(4)
Representative:
Noriyuki Umehara
(5)
Established:
January 2001
(6)
Start of operations:
June 2002
(7)
Employees:
1,902 (as of the end of October 2022)
(8)
Sales performance:
2,824,000 bottles per day
(average for the January-December 2021 period)
(9) Sales area:
Guangdong and Hainan Provinces
3. Profile of People's Republic of China
(1)
Population:
Approx. 1.41 billion
(2) Area:
Approx. 9.6 million km2 (about 25 times Japan)
(3)
Capital:
Beijing
(4)
Currency:
Chinese yuan
(5)
Exchange rate:
1 yuan = 20.35 yen (as of the end of October 2022)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Yakult Honsha Co. Ltd. published this content on 21 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 February 2023 05:49:04 UTC.
YAKULT HONSHA CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of dairy products and pharmaceuticals. The Company operates in three business segments. The Beverages and Food Manufacturing and Sale segment is engaged in the manufacture and sale of dairy products, beverages, noodles and healthy food, the purchase and sale of materials, as well as the transportation business. The Company operates business in Japan, the Americas, Europe, Asia and Oceania. The Pharmaceuticals Manufacturing and Sale segment is engaged in the manufacture and sale of anticancer drugs and other ethical drugs. The Others segment is engaged in the production and sale of cosmetics, as well as the operation of professional baseball clubs.